Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX958 in moderately to severely active Crohn's Disease
NCT05688852Phase 2Terminated
- Sponsor
- Ventyx Biosciences
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of cenacitinib in Crohn's disease (3 arms), sponsored by Ventyx Biosciences. Primary endpoint: Change in mean Crohn's Disease Activity Index (CDAI) score at 12 weeks. Started Jan 2023; status: terminated.
02
Drugs
cenacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05688852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688852.